Skip to main content
Fig. 6 | Parasites & Vectors

Fig. 6

From: Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo

Fig. 6

Body weight (a), hematocrit (b) and platelet counts (c) (mean ± standard deviation) of BALB/c mice inoculated with 1 × 107Babesia microti and treated with either vehicle, artesunate (ARS) 25 mg/kg, mefloquine (MEF) 50 mg/kg, tafenoquine (TAF) 10 mg/kg (base), ARS 25 mg/kg + MEF 50 mg/kg and ARS 25 mg/kg + TAF 10 mg/kg (base) (5 mice per group). a There was no significant difference in body weight changes between groups during infection, and mice in all groups showed a 3–10% increase of weight at day 20. b Hematocrit decreased in all groups and on days 8 and 12 the TAF alone group showed hematocrit levels higher than the other groups (P = 0.0317 compared to VEH group), except ARS + TAF group. The picture was similar on days 15 and 20, except that mice in the ARS only group had a recovery in hematocrit and showed no significant difference in relation to the TAF groups. c The profile of the platelet count decrease was similar to that of the hematocrit, decreasing in all groups on days 8 and 12 - the TAF alone group showed platelet counts higher than the other groups including the ARS + TAF group (P = 0.079 and 0.0456 compared to VEH on days 8 and 12, respectively). On day 20, only the groups VEH (P = 0.0159) and ARS + MEF (P = 0.0079) showed platelet counts significantly lower than the TAF group

Back to article page